Natural Capsules Limited FY26 Revenue Rose, EBITDA Turned Negative
Key highlights
- NCL’s FY26 revenue from operations increased 10.63% to Rs 187.20 crore.
- NCL’s EBITDA excluding other income moved from a Rs 17.52 crore profit in FY25 to a Rs 1.56 crore loss in FY26.
- NCL’s FY26 interest cost rose to Rs 17.14 crore from Rs 9.12 crore in FY25.
- NCL ended FY26 with total assets of Rs 424.16 crore and cash and cash equivalents of Rs 22 lakh.
powered by IRIS

NCL reported FY26 revenue from operations of Rs 187.20 crore, but EBITDA excluding other income turned to a Rs 1.56 crore loss as operating expenses reached Rs 188.76 crore, compared with EBITDA of Rs 17.52 crore in FY25. Interest cost also increased to Rs 17.14 crore from Rs 9.12 crore.
Know Natural Capsules inside out
Results, valuation, peers and who's buying, in one view.
Why did NCL report an EBITDA loss in FY26?
NCL reported a loss in earnings before interest, tax, depreciation and amortisation (EBITDA) of Rs 1.56 crore in FY26 because total operating expenses of Rs 188.76 crore exceeded revenue from operations of Rs 187.20 crore. In FY25, operating expenses were Rs 151.69 crore against revenue of Rs 169.21 crore, resulting in EBITDA of Rs 17.52 crore.
The year-on-year EBITDA movement was Rs 19.08 crore, even as revenue increased by Rs 17.99 crore. EBITDA margin moved to negative 0.83% in FY26 from 10.35% in FY25, extending a decline from 20.33% in FY23 and 12.81% in FY24.
Other income rose to Rs 1.73 crore in FY26 from Rs 0.70 crore in FY25, lifting total income to Rs 188.94 crore from Rs 169.91 crore. However, the increase in other income did not offset the Rs 37.07 crore rise in total operating expenses.
How did NCL’s profit after tax change in FY26?
NCL moved from a profit after tax of Rs 62 lakh in FY25 to a loss after tax of Rs 24.66 crore in FY26. Profit before tax excluding exceptional items changed from a profit of Rs 2.79 crore to a loss of Rs 27.92 crore over the same period.
Interest cost rose by Rs 8.02 crore to Rs 17.14 crore in FY26, while depreciation increased by Rs 4.64 crore to Rs 10.95 crore. These costs sit below EBITDA and contributed to the wider loss before tax after the operating result turned negative.
Earnings per share were negative 23.84 rupees in FY26, compared with positive 0.22 rupees in FY25. The presentation reports consolidated results, so the revenue, profit and per-share figures cover NCL’s group-level financial performance.
How fast did NCL’s revenue grow in FY26?
NCL’s revenue from operations increased 10.63% to Rs 187.20 crore in FY26 from Rs 169.21 crore in FY25. FY26 revenue exceeded the previous high of Rs 172.37 crore reported in FY23, following revenue of Rs 155.42 crore in FY24.
The revenue increase did not translate into operating profit because total operating expenses rose 24.44%, faster than revenue. Expenses increased from Rs 151.69 crore in FY25 to Rs 188.76 crore in FY26, creating the shift from a 10.35% EBITDA margin to a negative 0.83% margin.
NCL has stated that commercial sales from its active pharmaceutical ingredient, or API, facility began in Q4FY26 and that production is being scaled up with quality systems in place. Management’s priorities include increasing capsule sales in regulated markets, introducing capsule variants and developing steroidal and hormonal API molecules.
Got a follow-up? Ask IRIS
What changed in NCL’s balance sheet in FY26?
NCL’s total assets increased to Rs 424.16 crore at FY26 end from Rs 419.35 crore at FY25 end, a rise of Rs 4.81 crore. This was smaller than the expansion from Rs 288.71 crore in FY23 to Rs 376.53 crore in FY24 and Rs 419.35 crore in FY25.
Non-current assets declined to Rs 287.36 crore in FY26 from Rs 289.76 crore in FY25, while current assets increased to Rs 136.80 crore from Rs 129.59 crore. The FY26 asset increase therefore came from current assets rather than non-current assets.
Total equity, described by NCL as net worth, declined to Rs 234.72 crore from Rs 257.16 crore. Current liabilities increased to Rs 132.73 crore from Rs 99.99 crore, while non-current liabilities declined to Rs 56.71 crore from Rs 62.20 crore.
What do NCL’s cash flows show about investment spending?
NCL generated operating cash flow of Rs 10.92 crore in FY26, down from Rs 26.75 crore in FY25 but above the Rs 8.35 crore operating cash outflow in FY24. Investing activities used Rs 10.77 crore in FY26, leaving operating cash flow only Rs 15 lakh above the investment outflow before financing activities.
Investing cash outflows were higher in the preceding three financial years, at Rs 44.48 crore in FY25, Rs 72.59 crore in FY24 and Rs 104.63 crore in FY23. Financing activities generated Rs 87.49 crore in FY23 and Rs 81.72 crore in FY24, but used Rs 62 lakh in FY26.
Cash and cash equivalents ended FY26 at Rs 22 lakh, down from Rs 69 lakh at FY25 end. NCL recorded a net decrease in cash and cash equivalents of Rs 47 lakh in FY26, compared with a decrease of Rs 1.57 crore in FY25.
Conclusion
NCL’s FY26 performance shows that revenue growth to Rs 187.20 crore was outweighed by a larger increase in operating expenses to Rs 188.76 crore. The resulting Rs 1.56 crore EBITDA loss, higher interest cost of Rs 17.14 crore and depreciation of Rs 10.95 crore led to a Rs 24.66 crore loss after tax, while net worth declined to Rs 234.72 crore.
The next disclosed operational development is the scale-up of API production after commercial sales began in Q4FY26. Management also plans to expand capsule sales in regulated markets, develop API molecules and new capsule variants, while expecting about Rs 67 crore in production-linked incentive receipts over six years for eligible products.


